Chinese cancer drug developer InnoCare Pharma has priced its Hong Kong initial public offering at the top end of its marketing range to raise $288 million, said two sources, in the city's biggest float over the last two months.
Original Article: China biotech InnoCare raises $288 million in Hong Kong IPO: sources